News: OSE, Servier Complete Patient Enrollment In Sjogren's Syndrome Study

Nov 3 (Reuters) - OSE IMMUNOTHERAPEUTICS SA OSE.PA :

• SERVIER AND OSE IMMUNOTHERAPEUTICS ANNOUNCE COMPLETION OF PATIENT ENROLLMENT IN THE PHASE 2A CLINICAL TRIAL OF OSE-127/S95011 IN PRIMARY SJÖGREN'S SYNDROME
• STUDY INCLUDES 48 PATIENTS ACROSS A SCORE OF CENTERS LOCATED IN UNITED STATES, AUSTRALIA AND EUROPE
• RESULTS ARE EXPECTED IN 2023